Patents by Inventor Christopher Bieniarz

Christopher Bieniarz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8486620
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: July 16, 2013
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Patent number: 8481270
    Abstract: The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: July 9, 2013
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Richard Gniewek, Michael Farrell, Hiroaki Nitta, Megan Lehrkamp, Jerome Kosmeder, Brian Daniel Kelly, Thomas Grogan, Fabien Gaire, Mary Padilla, Christopher Bieniarz
  • Patent number: 8445191
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: May 21, 2013
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerome W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Publication number: 20130122516
    Abstract: Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.
    Type: Application
    Filed: July 1, 2011
    Publication date: May 16, 2013
    Inventors: Rui Hong, Hong Wang, Mark Lefever, Jan Froehlich, Christopher Bieniarz, Brian Kelly, Phillip Miller
  • Publication number: 20130115593
    Abstract: Embodiments of substrates and processes for chromogenic detection, and in particular pyrazolyl dihydrogen phosphate compounds, are disclosed.
    Type: Application
    Filed: August 12, 2011
    Publication date: May 9, 2013
    Applicant: Ventana Medical Systems, Inc.
    Inventors: Brian Daniel Kelly, Christopher Bieniarz, Hiro Nitta, Fabien Gaire
  • Publication number: 20130109019
    Abstract: Embodiments of hapten conjugates including a hapten, an optional linker, and a peroxidase-activatable aryl moiety are disclosed. In some embodiments, the peroxidase-activatable aryl moiety is tyramine or a tyramine derivative. Embodiments of methods for making and using the hapten conjugates also are disclosed. In particular embodiments, the hapten conjugates are used in a signal amplification assay. In certain embodiments, the hapten is an oxazole, a pyrazole, a thiazole, a benzofurazan, a triterpene, a urea, a thiourea other than a rhodamine thiourea, a nitroaryl other than dinitrophenyl or trinitrophenyl, a rotenoid, a cyclolignan, a heterobiaryl, an azoaryl, a benzodiazepine, or 7-diethylamino-3-carboxycoumarin. The hapten is coupled to the peroxidase-activatable aryl moiety directly or indirectly via a linker. In certain embodiments, the hapten conjugates are used in multiplexed assays.
    Type: Application
    Filed: July 1, 2011
    Publication date: May 2, 2013
    Inventors: Adrian E. Murillo, Jerome W. Kosmeder, Eric May, William Day, Mark Lefever, Anne M. Pedata, Christopher Bieniarz, Phillip Miller
  • Publication number: 20130034854
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Application
    Filed: April 27, 2011
    Publication date: February 7, 2013
    Applicant: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Publication number: 20130029376
    Abstract: The invention is directed to methods and compositions for deparaffinizing paraffin-embedded biological samples for subsequent tissue staining The compositions are microemulsions that may include water/oil/surfactant microemulsions, and optionally a cosurfactant. The microemulsions enable deparaffinization without the use of xylene or toluene, and also enable solvent exchange without the use of intermediary alcohol dehydration or alcohol rehydration compositions.
    Type: Application
    Filed: October 4, 2012
    Publication date: January 31, 2013
    Inventors: Brian H. Kram, Christopher Bieniarz, Paul D. Drumheller
  • Patent number: 8329401
    Abstract: The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: December 11, 2012
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Michael Farrell
  • Publication number: 20120283141
    Abstract: The invention is directed to enhanced methods for detecting an analyte of interest in situ, by immunoassay, or by hybridization comprising binding an enzyme-labeled conjugate molecule to an analyte of interest in the presence of a redox-inactive reductive species and a soluble metal ion. The enzyme catalyzes the conversion of the inactive reductive species to an active reducing agent, which in turn reduces the metal ion to a metal atom thereby providing an enhanced means of detecting the analyte via metal deposition.
    Type: Application
    Filed: June 21, 2012
    Publication date: November 8, 2012
    Inventors: Christopher Bieniarz, Michael Farrell
  • Publication number: 20120276584
    Abstract: A stabilized hematoxylin composition is disclosed that includes one or both of a host compound and an antioxidant. The disclosed composition exhibits sufficient stability to be utilized in an automated staining process without undue degradation prior to use of the composition to stain a biological sample. Methods of using and making the stabilized composition also are disclosed.
    Type: Application
    Filed: June 22, 2012
    Publication date: November 1, 2012
    Inventors: Jerome W. Kosmeder, Christopher Bieniarz, Penny Towne, Linda Willoughby Kivi
  • Patent number: 8288121
    Abstract: The invention is directed to methods and compositions for deparaffinizing paraffin-embedded biological samples for subsequent tissue staining. The compositions are microemulsions that may include water/oil/surfactant microemulsions, and optionally a cosurfactant. The microemulsions enable deparaffinization without the use of xylene or toluene, and also enable solvent exchange without the use of intermediary alcohol dehydration or alcohol rehydration compositions.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: October 16, 2012
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Brian H. Kram, Christopher Bieniarz, Paul D. Drumheller
  • Patent number: 8263361
    Abstract: A stabilized hematoxylin composition is disclosed that includes one or both of a host compound and an antioxidant. The disclosed composition exhibits sufficient stability to be utilized in an automated staining process without undue degradation prior to use of the composition to stain a biological sample. Methods of using and making the stabilized composition also are disclosed.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: September 11, 2012
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerome W. Kosmeder, Christopher Bieniarz, Penny Towne, Linda Willoughby Kivi
  • Publication number: 20120219948
    Abstract: Embodiments of a system, method, and kit for visualizing a nucleus are disclosed. A tissue sample is pretreated with a protease to permeabilize the nucleus, and then incubated with a nanoparticle/DNA-binding moiety conjugate. The DNA-binding moiety includes at least one DNA-binding molecule. The conjugate binds to DNA within the nucleus, and the nanoparticle is visualized, thereby visualizing the nucleus. Computer and image analysis techniques are used to evaluate nuclear features such as chromosomal distribution, ploidy, shape, size, texture features, and/or contextual features. The method may be used in combination with other multiplexed tests on the tissue sample, including fluorescence in situ hybridization. Kits for performing the method include a protease enzyme composition, a nanoparticle/DNA-binding moiety conjugate, and a reaction buffer.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 30, 2012
    Inventors: Chol Steven Yun, Brian Daniel Kelly, Julia Ashworth-Sharpe, Christopher A. Bieniarz, Pascal Bamford, Adrian E. Murillo
  • Publication number: 20110245098
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Application
    Filed: April 29, 2011
    Publication date: October 6, 2011
    Inventors: Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Publication number: 20110244544
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Application
    Filed: May 2, 2011
    Publication date: October 6, 2011
    Inventors: Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Publication number: 20110244545
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Application
    Filed: May 2, 2011
    Publication date: October 6, 2011
    Inventors: Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Patent number: 7985557
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: July 26, 2011
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerry W. Kosmeder, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Publication number: 20110136130
    Abstract: The present invention provides a method and kit for detection of two or more target molecules in a single tissue sample, such as for gene and protein dual detection in a single tissue sample. Methods comprise treating a tissue sample with a first binding moiety that specifically binds a first target molecule. Methods further comprise treating the tissue sample with a solution containing a soluble electron-rich aromatic compound prior to or concomitantly with contacting the tissue sample with a hapten-labeled binding moiety and detecting a second target molecule. In one example, the first target molecule is a protein and the second is a nucleic acid sequence, the first target molecule being detected by immunohistochemistry and the second by in situ hybridization. The disclosed method reduces background due to non-specific binding of the hapten-labeled specific binding moiety to an insoluble electron rich compound deposited near the first target molecule.
    Type: Application
    Filed: August 21, 2009
    Publication date: June 9, 2011
    Inventors: Richard Gniewek, Michael Farrell, Hiroaki Nitta, Megan Lehrkamp, Jerome Kosmeder, Brian Daniel Kelly, Fabien Gaire, Mary Padilla, Thomas Grogan, Christopher Bieniarz
  • Publication number: 20100297725
    Abstract: A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.
    Type: Application
    Filed: March 2, 2010
    Publication date: November 25, 2010
    Inventors: Jerome W. Kosmeder, Mark Lefever, Donald Johnson, Michael Farrell, Zhanna Zhilina, Christopher Bieniarz